NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Wednesday reported a loss of $245.1 million in its third quarter.
The Novato, California-based company said it had a loss of $3.50 per share. Losses, adjusted for costs related to mergers and acquisitions, came to $2.43 per share.
The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $2.29 per share.
The biotechnology company posted revenue of $90.7 million in the period, which also missed Street forecasts. Eight analysts surveyed by Zacks expected $98.8 million.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News